Targeting of AKT/ERK/CTNNB1 by DAW22 as a potential therapeutic compound for malignant peripheral nerve sheath tumor

Area of Science:

• Oncology
• Pharmacology
• Natural Products Chemistry

Background:

• Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive neoplasms with poor prognosis and limited treatment options.
• MPNSTs are associated with neurofibromatosis type 1 (NF1) and involve aberrant RAS/RAF/MEK/ERK, PI3K/AKT/mTOR, and WNT/CTNNB1 signaling.
• Current therapeutic strategies for MPNSTs are insufficient, necessitating novel treatment approaches.

Purpose of the Study:

• To investigate the anti-cancer potential of DAW22, a natural compound from Ferula ferulaeoides, against MPNSTs.
• To elucidate the molecular mechanisms by which DAW22 affects MPNST progression.
• To evaluate the efficacy of DAW22 in reducing MPNST tumor growth in vivo.

Main Methods:

• In vitro studies using five human MPNST cell lines to assess proliferation and colony formation.
• Western blot analysis to examine the impact of DAW22 on key signaling pathway components (AKT, ERK, CTNNB1).
• In vivo xenograft mouse model to evaluate DAW22's effect on tumor growth over 25 days.

Main Results:

• DAW22 significantly inhibited cell proliferation and colony formation in human MPNST cell lines.
• DAW22 suppressed phosphorylation of AKT and ERK, and reduced active CTNNB1 levels, indicating pathway modulation.
• Daily DAW22 treatment in a xenograft mouse model led to a significant reduction in tumor growth.

Conclusions:

• DAW22 demonstrates potent anti-tumor activity against MPNSTs through multi-targeted signaling pathway inhibition.
• DAW22 represents a promising natural compound for the development of novel MPNST therapeutics.
• Further research into DAW22 could lead to effective treatment strategies for this aggressive cancer.